Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab ; volume:11 ; number:1 ; day:13 ; month:1 ; year:2021 ; pages:1-12 ; date:12.2021
Scientific reports ; 11, Heft 1 (13.1.2021), 1-12, 12.2021
- Creator
-
Nissen, Neel I.
Kehlet, Stephanie
Boisen, Mogens K.
Liljefors, Maria
Jensen, Christina
Johansen, Astrid Z.
Johansen, Julia S.
Erler, Janine T.
Karsdal, Morten
Mortensen, Joachim H.
Høye, Anette
Willumsen, Nicholas
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-020-79608-0
- URN
-
urn:nbn:de:101:1-2021020722045066080480
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nissen, Neel I.
- Kehlet, Stephanie
- Boisen, Mogens K.
- Liljefors, Maria
- Jensen, Christina
- Johansen, Astrid Z.
- Johansen, Julia S.
- Erler, Janine T.
- Karsdal, Morten
- Mortensen, Joachim H.
- Høye, Anette
- Willumsen, Nicholas
- SpringerLink (Online service)
Other Objects (12)
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report
Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa
Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report
Periodontal disease in a patient receiving Bevacizumab: a case report
Brain microischemic phenomena in a woman receiving bevacizumab treatment: a case report
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
Modified FOLFOX-6 Plus Bevacizumab Chemotherapy for Metastatic Colorectal Cancer in Patients Receiving Hemodialysis: A Report of Three Cases and Review of the Literature
Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report
Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa
Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report
Periodontal disease in a patient receiving Bevacizumab: a case report
Brain microischemic phenomena in a woman receiving bevacizumab treatment: a case report
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
Modified FOLFOX-6 Plus Bevacizumab Chemotherapy for Metastatic Colorectal Cancer in Patients Receiving Hemodialysis: A Report of Three Cases and Review of the Literature
Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report
Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa
Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report
Periodontal disease in a patient receiving Bevacizumab: a case report
Brain microischemic phenomena in a woman receiving bevacizumab treatment: a case report
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
Modified FOLFOX-6 Plus Bevacizumab Chemotherapy for Metastatic Colorectal Cancer in Patients Receiving Hemodialysis: A Report of Three Cases and Review of the Literature
Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice